Announcements Trials
Browse Landscape

Phase

Phase 4 2Phase 2 2Phase NA 1

Status

Unknown 4Completed 2

Sponsor Class

INDUSTRY 3OTHER 2NIH 1

Study Type

Interventional 5Observational 1

Sponsor

Cancer Type

Tumor-Agnostic 2Genitourinary 2Gynecologic 1Gastrointestinal 1

Conditions

Neoplasms 3Recurrence 2Wilms Tumor 1Ovarian Neoplasms 1Neoplasm Metastasis 1Fallopian Tube Neoplasms 1Death 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Ovarian Epithelial 1

Interventions

Cisplatin 3193Cyclophosphamide 3187Carboplatin 2968Radiotherapy 2784Paclitaxel 2716Gemcitabine 2569pembrolizumab 2378Bevacizumab 2206Docetaxel 2196Fluorouracil 1848Capecitabine 1828Oxaliplatin 1738Dexamethasone 1604Nivolumab 1580Doxorubicin 1501Rituximab 1487Magnetic Resonance Spectroscopy 1382Etoposide 1345Irinotecan 1245Leucovorin 1222Drug Therapy 1202Cytarabine 1130Pemetrexed 1074fludarabine 1056Specimen Handling 1009Vincristine 964Cetuximab 943Prednisone 940Trastuzumab 940Lenalidomide 937

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Genes, p53 × Clear all
NCT04758455 2021-02-17

The Use of Immunohistochemical Staining for the Prediction of Wilms Tumour Progression and Recurrence

Mansoura University

Phase NA Unknown
75 enrolled
Genitourinary

Death, Wilms Tumor, Recurrence

NCT03467308 2020-05-11

Signaling Pathways Targeting Colorectal Cancer in Egypt

Assiut University

Completed
180 enrolled
Gastrointestinal

Colorectal Neoplasms

NCT02435186 2015-05-06

p53 Gene in Treatment of Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer

Shenzhen SiBiono GeneTech Co.,Ltd

Phase 2 Unknown
100 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms, Recurrence

NCT00894153 2012-04-09

p53 Gene Therapy for Head and Neck Malignant Tumors in Advanced Stage

Shenzhen SiBiono GeneTech Co.,Ltd

Phase 4 Unknown
1,200 enrolled
Tumor-Agnostic

Neoplasms

NCT00902083 2012-04-09

rAd-p53

Shenzhen SiBiono GeneTech Co.,Ltd

Phase 4 Unknown
600 enrolled
Tumor-Agnostic

Neoplasms

NCT00393029 2011-08-15

Phase II Study of Metastatic Cancer That Overexpresses P53 Using Lymphodepleting Conditioning Followed by Infusion of Anti-P53 TCR-Gene Engineered Lymphocytes

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
12 enrolled 10 charts
Genitourinary

Carcinoma, Renal Cell, Neoplasm Metastasis, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡